Learn how AI in drug discovery is revolutionizing therapeutic development and addressing challenges in cell and gene therapy.

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fu ...

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patie ...

Fortrea forecasts revenue and EBITDA declines for 2025. With a $477.16M market cap, financial improvement could drive stock ...

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...

In 2014, the clinical development success rate stood at 10.4%; just over one in every 10 drugs that entered a Phase I clinical ... clinical trials in a more cost-effective manner.

Topping the chart for off ... allowing for research and development costs. Big Pharma argues this is a huge financial burden. But is it really? Take pembrolizumab, a drug that uses an adapted ...

23andMe's big push into drug development ... shown by our clinical and preclinical stage pipeline and will continue to pursue strategic opportunities to continue their development," said Wojcicki.

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...